FDA Approves ICOTYDE — the First Oral Peptide That Targets IL-23 for Psoriasis

The FDA approved ICOTYDE (icotrokinra) on March 18, 2026, making it the first and only oral peptide designed to block the interleukin-23 (IL-23) receptor — a key driver of the inflammatory response behind plaque psoriasis. Developed by Protagonist Therapeutics (Nasdaq: PTGX) in collaboration with Johnson & Johnson (NYSE: JNJ), the drug represents a paradigm shift for the roughly 7.5 million Americans living with psoriasis.

Why This Approval Is a Big Deal

Until now, patients with moderate-to-severe plaque psoriasis who needed systemic treatment had two main paths: injectable biologics (like Skyrizi, Tremfya, or Cosentyx) that target the IL-23 or IL-17 pathways, or older oral drugs (like methotrexate or apremilast) that work through broader immunosuppression. ICOTYDE, an oral cyclic peptide, bridges the gap — offering the targeted precision of a biologic in the convenience of a daily pill.

In the pivotal VOYAGE-1 and VOYAGE-2 trials, icotrokinra delivered complete skin clearance (PASI 100) in a significant proportion of patients, with a safety profile that Johnson & Johnson described as favorable compared to both injectable biologics and traditional oral therapies.

How Oral Peptides Reached This Point

Icotrokinra is a synthetic cyclic peptide — a class of molecules that are inherently more stable than linear peptides and can resist degradation in the gastrointestinal tract. Protagonist Therapeutics pioneered this approach, engineering peptides that maintain their three-dimensional structure through oral delivery.

This is the same platform technology behind rusfertide, Protagonist's approved treatment for polycythemia vera. The ICOTYDE approval validates the broader thesis that oral peptides can match the efficacy of injected biologics for autoimmune diseases — a market worth over $80 billion globally.

What It Means for Patients

For people with moderate-to-severe psoriasis, ICOTYDE offers something genuinely new: biologic-level efficacy without needles, without infusion centers, and without the cold-chain storage requirements of injectable drugs. The once-daily pill form factor could also improve treatment adherence, a persistent challenge in dermatology where many patients discontinue therapy.

Johnson & Johnson is positioning ICOTYDE as a first-line systemic option — not just a fallback for patients who fail other therapies. If insurance coverage follows, this could fundamentally change prescribing patterns in dermatology.

The Broader Oral Peptide Wave

ICOTYDE joins a growing roster of oral peptide therapies reaching the market in 2026. Combined with the oral GLP-1 drugs reshaping metabolic disease treatment, these approvals are dismantling the long-held assumption that peptides require injection to be effective. The technology is now proven across multiple therapeutic areas — from metabolic disease to autoimmune disorders — and the pipeline is only accelerating.